viDA is developing first-in-class drugs targeting a key enzyme involved in pathogenesis of chronic age related inflammatory and autoimmune diseases. Lead program involves topically delivering proprietary protease inhibitor to treat radiation dermatitis to achieve rapid clinical proof of concept. Platform value due to additional therapeutic opportunities topically targeting in other skin diseases as well as systemic approaches to treat other autoimmune and chronic inflammatory diseases. (BIOTECanada)(LSBC)